Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD Patients With Myopathy and/or Cardiomyopathy and Inflammation (PMD-OPTION)

NCT05972954 is registered in ClinicalTrials.gov with Omeicos Therapeutics GmbH as lead sponsor.

NCT NCT05972954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05972954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD Patients With Myopathy and/or Cardiomyopathy and Inflammation (PMD-OPTION)
Lead sponsor
Omeicos Therapeutics GmbH
Phase
Phase 2
Overall status
Completed
Start date
May 22, 2023
Completion date
July 30, 2025
Enrollment
28 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

primary mitochondrial disease